- Algernon Pharmaceuticals announced that Ifenprodil reduced interleukin 6 in its recent Ifenprodil Phase 2b/3 COVID-19 trial
- One of the biomarkers that were measured in the COVID-19 trial was the change in IL-6 levels
- The effects of Ifenprodil on IL-6 may be helpful in better understanding its potential role as a possible therapeutic treatment for idiopathic pulmonary fibrosis (IPF)
- The company recently announced it had achieved 50% of its enrollment target for its Phase 2 trial of Ifenprodil for IPF and chronic cough
- Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) is up 3.23 per cent, trading at C$0.16 per share at 10:15 am ET
Algernon Pharmaceuticals announced that NP-120 (Ifenprodil) reduced interleukin 6 (IL-6) in its recent Ifenprodil Phase 2b/3 COVID-19 trial.
This may be significant for the company’s ongoing Phase 2 trial of Ifenprodil for idiopathic pulmonary fibrosis (IPF) and chronic cough.
The company reports that in the COVID-19 trial, one of the biomarkers that were measured was the change in IL-6 levels. In the measurement from baseline to day five, IL-6 was reduced in the 20 mg treatment arm by 267 ng/L, versus 7 ng/L in the standard of care arm.
IL-6, both a pro-inflammatory cytokine and an anti-inflammatory myokine, is encoded by the IL-6 gene. IL-6 can promote fibrosis by driving chronic inflammation and is elevated in patients with IPF.
Blockade of IL-6 has been shown to attenuate pulmonary fibrosis in a mouse model.
The effects of Ifenprodil on IL-6 may be helpful in better understanding its potential role as a possible therapeutic treatment for IPF.
The company recently announced it had achieved 50% of its enrollment target for its Phase 2 trial of Ifenprodil for IPF and chronic cough.
Changes in IL-6 will be measured in this study, along with other markers of fibrosis such as C-reactive protein and collagen pro-peptides.
Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) is up 3.23 per cent, trading at C$0.16 per share at 10:15 am ET.
